S'abonner

Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphate - 01/07/16

Doi : 10.1016/j.jaci.2015.10.044 
Sara J. Bonvini, PhD a, ∗, Mark A. Birrell, PhD a, ∗, Megan S. Grace, PhD b, Sarah A. Maher, PhD a, John J. Adcock, PhD a, Michael A. Wortley, PhD a, Eric Dubuis, PhD a, Yee-Man Ching, MRes c, Anthony P. Ford, PhD e, Fisnik Shala, MD a, Montserrat Miralpeix, PhD f, Gema Tarrason, PhD f, Jaclyn A. Smith, PhD d, Maria G. Belvisi, PhD a, ⁎
a Respiratory Pharmacology Group, Airway Disease Section, National Heart & Lung Institute, Imperial College London, London, United Kingdom 
c Airway Disease Infection Section, National Heart & Lung Institute, Imperial College London, London, United Kingdom 
b School of Medical Sciences and Health Innovations Research Institute, RMIT University, Bundoora, Australia 
d Respiratory and Allergy Centre, University of Manchester, University Hospital of South Manchester, Manchester, United Kingdom 
e Afferent Pharmaceuticals, San Mateo, Calif 
f Respiratory Therapeutic Area–Discovery, R&D Centre, Almirall S.A., Barcelona, Spain 

∗Corresponding author: Maria G. Belvisi, PhD, Respiratory Pharmacology Group, Airway Disease Section, National Heart & Lung Institute, Imperial College, Exhibition Road, London SW7 2AZ, United Kingdom.Respiratory Pharmacology GroupAirway Disease SectionNational Heart & Lung InstituteImperial CollegeExhibition RoadLondonSW7 2AZUnited Kingdom

Abstract

Background

Sensory nerves innervating the airways play an important role in regulating various cardiopulmonary functions, maintaining homeostasis under healthy conditions and contributing to pathophysiology in disease states. Hypo-osmotic solutions elicit sensory reflexes, including cough, and are a potent stimulus for airway narrowing in asthmatic patients, but the mechanisms involved are not known. Transient receptor potential cation channel, subfamily V, member 4 (TRPV4) is widely expressed in the respiratory tract, but its role as a peripheral nociceptor has not been explored.

Objective

We hypothesized that TRPV4 is expressed on airway afferents and is a key osmosensor initiating reflex events in the lung.

Methods

We used guinea pig primary cells, tissue bioassay, in vivo electrophysiology, and a guinea pig conscious cough model to investigate a role for TRPV4 in mediating sensory nerve activation in vagal afferents and the possible downstream signaling mechanisms. Human vagus nerve was used to confirm key observations in animal tissues.

Results

Here we show TRPV4-induced activation of guinea pig airway–specific primary nodose ganglion cells. TRPV4 ligands and hypo-osmotic solutions caused depolarization of murine, guinea pig, and human vagus and firing of Aδ-fibers (not C-fibers), which was inhibited by TRPV4 and P2X3 receptor antagonists. Both antagonists blocked TRPV4-induced cough.

Conclusion

This study identifies the TRPV4-ATP-P2X3 interaction as a key osmosensing pathway involved in airway sensory nerve reflexes. The absence of TRPV4-ATP–mediated effects on C-fibers indicates a distinct neurobiology for this ion channel and implicates TRPV4 as a novel therapeutic target for neuronal hyperresponsiveness in the airways and symptoms, such as cough.

Le texte complet de cet article est disponible en PDF.

Key words : Transient receptor potential, sensory nerves, vagus, cough, ion channels, hypotonicity, ATP

Abbreviations used : AUC, [Ca2+]i, COPD, CV, DiI, DMSO, ECS, K50, αβ-MeATP, NCBI, 4α-PDD, Px1, RAR, TRP, TRPV4


Plan


 Supported by S.A.M., M.S.G., E.D. were funded by project grants from the Medical Research Council (MRC, UK; M.S.G.: G0800195; S.A.M. and E.D.: MR/K020293/1). M.A.W., Y.-M.C., and S.J.B. were supported on an MRC studentship, an MRC/Asthma UK Centre studentship, and the National Heart and Lung Institute, respectively. M.A.W. was also funded by the North West Lung Centre Charity. The human vagus experiments in this study were undertaken with the support of the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London and the Imperial Confidence in Concept Fund.
 Disclosure of potential conflict of interest: A. P. Ford is employed by Afferent Pharma. M. Miralpeix and G. Tarrason are employed by Almirall S.A. J. A. Smith has consultant arrangements with Verona Pharma plc, GlaxoSmithKline, Almirall, Reckitt Benckiser, Glenmark, Xention, Patara, Bayer, and Aboca; has received grants from Verona Pharma, the British Lung Foundation, the Medical Research Council Industry Collaboration Agreement research grant with Almirall, MRC AstraZeneca Mechanisms of Disease, GlaxoSmithKline, Xention, Afferent, Medical Research Council Fellowship, Moulton Charitable Trust, and NeRRe; is an inventor on a patent owned by University Hospital of South Manchester for Vitalograph; has received payment for development of educational presentations from GlaxoSmithKline; and has received travel support from GlaxoSmithKline. M. G. Belvisi has received grants from the Medical Research Council, Afferent, the North West Lung Centre Charity, the National Institute for Health Research Respiratory Disease Biomedical Research Unit and the Royal Brompton and Harefield NHS Foundation Trust, and Imperial College London and the Imperial Confidence Concept Fund; is an associate editor for the American Journal of Respiratory and Critical Care Medicine; is an executive editor for Pharmacology and Therapeutics; has consultant arrangements with Ario Pharma, Aboca, Chiesi Pharma, Imperial College Consultants, Patara, Pulmatrix, Sun Pharma, and Skye Pharma; and is Director of IR Pharma, an Imperial College spinout that conducts contract research. The rest of the authors declare that they have no relevant conflicts of interest.


© 2015  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 138 - N° 1

P. 249 - juillet 2016 Retour au numéro
Article précédent Article précédent
  • Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases
  • Francesca Conti, Saul Oswaldo Lugo-Reyes, Lizbeth Blancas Galicia, Jianxin He, Güzide Aksu, Edgar Borges de Oliveira, Caroline Deswarte, Marjorie Hubeau, Neslihan Karaca, Maylis de Suremain, Antoine Guérin, Laila Ait Baba, Carolina Prando, Gloria G. Guerrero, Melike Emiroglu, Fatma Nur Öz, Marco Antonio Yamazaki Nakashimada, Edith Gonzalez Serrano, Sara Espinosa, Isil Barlan, Nestor Pérez, Lorena Regairaz, Héctor Eduardo Guidos Morales, Liliana Bezrodnik, Daniela Di Giovanni, Ghassan Dbaibo, Fatima Ailal, Miguel Galicchio, Matias Oleastro, Jalel Chemli, Silvia Danielian, Laura Perez, Maria Claudia Ortega, Susana Soto Lavin, Joseph Hertecant, Ozden Anal, Nadia Kechout, Eman Al-Idrissi, Gehad ElGhazali, Anastasia Bondarenko, Liudmyla Chernyshova, Peter Ciznar, Rose-Marie Herbigneaux, Aminata Diabate, Stéphanie Ndaga, Barik Konte, Ambre Czarna, Mélanie Migaud, Sigifredo Pedraza-Sánchez, Mussaret Bano Zaidi, Guillaume Vogt, Stéphane Blanche, Imen Benmustapha, Davood Mansouri, Laurent Abel, Stéphanie Boisson-Dupuis, Nizar Mahlaoui, Ahmed Aziz Bousfiha, Capucine Picard, Ridha Barbouche, Saleh Al-Muhsen, Francisco J. Espinosa-Rosales, Necil Kütükçüler, Antonio Condino-Neto, Jean-Laurent Casanova, Jacinta Bustamante
| Article suivant Article suivant
  • Epicutaneous immunization with ovalbumin and CpG induces TH1/TH17 cytokines, which regulate IgE and IgG2a production
  • Monika Majewska-Szczepanik, Philip W. Askenase, Francis M. Lobo, Katarzyna Marci?ska, Li Wen, Marian Szczepanik

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.